Judith G. Deal

Publications by Year

Research Areas

Biochemical and Molecular Research, Cancer therapeutics and mechanisms, Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Cancer-related Molecular Pathways

Most-Cited Works

• → Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations(2014)574 cited
• → Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones(1993)161 cited
• → Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib(2014)117 cited
• → Crystal-structure-based design and synthesis of benz[cd]indole-containing inhibitors of thymidylate synthase(1992)116 cited
• → Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR(2017)89 cited
• → Structure-Based Design of Substituted Diphenyl Sulfones and Sulfoxides as Lipophilic Inhibitors of Thymidylate Synthase(1997)43 cited
• → Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)(2020)40 cited
• → CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety(2025)39 cited
• → Synthesis and Biological Evaluation of Novel 2,6-Diaminobenz[cd]indole Inhibitors of Thymidylate Synthase Using the Protein Structure as a Guide(1995)33 cited
• → Design, Synthesis, and Biological Activity of Novel Polycyclic Aza-Amide FKBP12 Ligands(2006)22 cited